CD45.1 anticorps (PE-Cy7)

N° du produit ABIN375560

Détail du produit anti-CD45.1 anticorps (PE-Cy7)

Antigène: CD45.1 (CD45 (CD45.1 Allogen))

Reactivité: Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD45.1 est conjugé à/à la PE-Cy7

Application: Flow Cytometry (FACS)

Specificité: Mouse CD45.1, Mr 180-240 kDa

Attributs du produit: Mouse Anti-Mouse CD45.1-PE/CY7

Purification: Purified

Immunogène: SJL mouse thymocytes and splenocytes

Clone: A20

Isotype: IgG2a

Information d'application

Indications d'application:

• Applications: FC - Quality tested , IHC-FS - Reported in literature , IHC-PS - Reported in literature
• Working Dilutions: Flow Cytometry FITC, BIOT, and AF488 conjugates 1 g/106 cells PACBLU conjugate 0.3 g/106 cells PE, APC, SPRD, CY5, PE/CY5.5, PE/CY7, APC/CY5.5, 0.2 g/106 cells APC/CY7, and AF647 conjugates For flow cytometry, the suggested use of these reagents is in a final volume of 100 L

Volume d'échantillon: 1 mL

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: 0.1 mg in 0.2 mL of PBS/Sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect conjugated products from light.
Each reagent is stable for the period shown on the bottle label if stored as directed.

Stock: 4 °C

Stockage commentaire: Store at 2-8°C

Détails sur CD45.1

Antigène: CD45.1 (CD45 (CD45.1 Allogen))

Autre désignation: CD45.1 (CD45.1 Produits)

Sujet: The CD45 antigen is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants (CD45R) and as allelic forms CD45.1/Ly-5.1 and CD45.2/Ly-5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies where resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation.